Melissa Dinolfo

478 total citations
7 papers, 363 citations indexed

About

Melissa Dinolfo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Melissa Dinolfo has authored 7 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Melissa Dinolfo's work include Colorectal Cancer Treatments and Studies (2 papers), Lung Cancer Treatments and Mutations (2 papers) and SARS-CoV-2 and COVID-19 Research (1 paper). Melissa Dinolfo is often cited by papers focused on Colorectal Cancer Treatments and Studies (2 papers), Lung Cancer Treatments and Mutations (2 papers) and SARS-CoV-2 and COVID-19 Research (1 paper). Melissa Dinolfo collaborates with scholars based in United States and Singapore. Melissa Dinolfo's co-authors include Lee S. Rosen, Marilyn Mulay, Masahiro Sugawara, Chisato Tomoda, Elaine K. Wong, Jerome M. Hershman, Richie Soong, Carlo L. Bello, Kaku Saito and Ross A. Soo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Melissa Dinolfo

7 papers receiving 356 citations

Peers

Melissa Dinolfo

ONCOL

PRM

MB

EPIDE

SURGE

Tomohiro Funakoshi United States

Jean-François Caubet United States

Christopher J. Darus United States

Marie Bretagne France

Tetsuya Urasaki Japan

Claude Darte United States

Iwao Ono Japan

Nathan D. Seligson United States

Maria Ossolińska Poland

Chatchawin Assanasen United States

Tomohiro Funakoshi United States

Melissa Dinolfo

111 ×0.5

ONCOL

110 ×0.7

PRM

96 ×0.9

MB

37 ×0.5

EPIDE

51 ×0.9

SURGE

Citations per year, relative to Melissa Dinolfo Melissa Dinolfo (= 1×) peers Tomohiro Funakoshi

Countries citing papers authored by Melissa Dinolfo

Since Specialization

Citations

This map shows the geographic impact of Melissa Dinolfo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Dinolfo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Dinolfo more than expected).

Fields of papers citing papers by Melissa Dinolfo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Dinolfo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Dinolfo. The network helps show where Melissa Dinolfo may publish in the future.

Co-authorship network of co-authors of Melissa Dinolfo

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Dinolfo. A scholar is included among the top collaborators of Melissa Dinolfo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Dinolfo. Melissa Dinolfo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Srinivasan, Vinay, et al.. (2022). On variants and vaccines: The effectiveness of Covid-19 monoclonal antibody therapy during two distinct periods in the pandemic. PLoS ONE. 17(12). e0278394–e0278394. 1 indexed citations

2.

Chuah, Benjamin, Boon Cher Goh, Richie Soong, et al.. (2010). Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients. Cancer Science. 102(2). 478–483. 105 indexed citations

3.

Bello, Carlo L., Marilyn Mulay, Xin Huang, et al.. (2009). Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib. Clinical Cancer Research. 15(22). 7045–7052. 74 indexed citations

4.

Mendelson, David S., Melissa Dinolfo, Richard B. Cohen, et al.. (2008). First-in-human dose escalation safety and pharmacokinetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3524–3524. 5 indexed citations

5.

Rosen, Lee S., Isett Laux, Melissa Dinolfo, et al.. (2008). A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. Journal of Clinical Oncology. 26(15_suppl). 14585–14585. 15 indexed citations

6.

Wong, Elaine K., Lee S. Rosen, Marilyn Mulay, et al.. (2007). Sunitinib Induces Hypothyroidism in Advanced Cancer Patients and May Inhibit Thyroid Peroxidase Activity. Thyroid. 17(4). 351–355. 159 indexed citations

7.

Bello, Carlo L., Marilyn Mulay, Melissa Dinolfo, et al.. (2007). 709 POSTER Characterization of electrocardiographic QTc interval in patients (pts) with advanced solid tumors: pharmacokinetic–pharmacodynamic evaluation of sunitinib. European Journal of Cancer Supplements. 5(4). 110–110. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact